Seattle Genetics (ticker: SGEN, exchange: NASDAQ Global Market (.O))
News Release -
Seattle Genetics Appoints Vice President, Medical Affairs and
Announces Vice President, Quality Management Promotion
BOTHELL, Wash., Oct 26, 2011 (BUSINESS WIRE) --
Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the appointment of
James Kyle Bryan, M.D., as Vice President, Medical Affairs. Dr. Bryan is
a hematologist and medical oncologist, and brings more than 18 years of
experience in oncology drug development. In addition, the company
announced the promotion of Charles Smith to Vice President, Quality. Mr.
Smith joined Seattle Genetics in 2003, and has played a key leadership
role in the company's Technical Operations group, including successful
regulatory inspections to support the recent U.S. Food and Drug
Administration approval of ADCETRIS(TM) (brentuximab vedotin).
"Kyle brings a wealth of industry experience and outstanding
relationships with thought leaders in the field of oncology," said
Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle
Genetics. "We look forward to his contributions at Seattle Genetics as
he brings his proven leadership abilities and commitment to helping
patients to our Medical Affairs team."
Prior to joining Seattle Genetics, Dr. Bryan was at PPD, Inc., a global
contract research organization. He served most recently as Vice
President of Global Product Development, working within a group of PPD
medical specialists providing internal and external strategic consulting
services. In this role he was the head of the therapeutic group for all
hematology- and oncology-based services. Prior to joining PPD, Dr. Bryan
was Director of Clinical Research at NeoRx Corporation (now Poniard
Pharmaceuticals), a biotechnology company based in Seattle. In addition
to his industry experience, Dr. Bryan was in the private practice of
hematology and medical oncology and is currently a member of the
teaching faculty at the University of Washington Medical Center. Dr.
Bryan received a B.S. in Biochemistry and an M.D. from Louisiana State
University and did his fellowship in hematology and oncology at the
University of Washington.
Since joining Seattle Genetics more than eight years ago, Charles Smith
has established the quality assurance (QA) function and oversight for
all good manufacturing practices (GMP), good laboratory practices (GLP)
and good clinical practices (GCP) activities and led the development of
the quality control (QC) laboratory function. He has also contributed to
the preparation of the chemistry, manufacturing and controls (CMC)
sections for multiple regulatory submissions.
"Charles has been an integral part of our development team since joining
the company more than eight years ago, including his management of the
QA and QC functions that supported the recent commercial release of
ADCETRIS," said Vaughn B. Himes, Ph.D., Executive Vice President,
Technical Operations at Seattle Genetics. "He has demonstrated
significant leadership and strategic capabilities, and a commitment to
the highest quality standards for Seattle Genetics products."
Prior to joining Seattle Genetics, Mr. Smith spent seven years at
Targeted Genetics, most recently as Senior Director of Quality Control.
Before that, he spent 11 years at Genentech in increasing roles of
responsibility, including Manager of Quality Control Clinical
Development. Mr. Smith received his B.A. in Molecular and Cellular
Genetics from Humboldt State University and holds the CQA certifications
for Quality Engineer and Quality Auditor.
About Seattle Genetics
Seattle Genetics is a biotechnology company focused on the development
and commercialization of monoclonal antibody-based therapies for the
treatment of cancer. ADCETRIS(TM) was approved by the FDA on August 19,
2011 for two indications. ADCETRIS is being developed in collaboration
with Millennium: The Takeda Oncology Company. In addition, Seattle
Genetics has three other clinical-stage ADC programs: SGN-75, ASG-5ME
and ASG-22ME. Seattle Genetics has collaborations for its ADC technology
with a number of leading biotechnology and pharmaceutical companies,
including Abbott, Bayer, Celldex Therapeutics, Daiichi Sankyo,
Genentech, GlaxoSmithKline, Millennium, Pfizer and Progenics, as well as
ADC co-development agreements with Agensys, an affiliate of Astellas,
and Genmab. More information can be found at www.seattlegenetics.com.
SOURCE: Seattle Genetics, Inc.
Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160